

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

IN RE SELENIOUS ACID LITIGATION

C.A. No. 2:24-7791-BRM-CLW  
(consolidated)

**CONSENT JUDGMENT**

American Regent, Inc. (“ARI”) and Gland Pharma Limited (collectively, “GLAND”), parties in the above-captioned Action, specifically in the Action initiated by Plaintiff, ARI, against GLAND in Civil Action No. 24-cv-07802; 2:24-cv-11116 and 2:24-cv-7791-BRM-CLW, have resolved these litigations for good cause and valuable consideration recognized by ARI and GLAND. Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the Actions, as follows:

IT IS this \_\_\_\_ day of \_\_\_\_\_, 2025:

ORDERED, ADJUDGED AND DECREED as follows:

1. This District Court has jurisdiction over the subject matter of the above Actions and has personal jurisdiction over the parties.

2. As used in this Consent Judgment, (i) the term “GLAND Product” shall mean the drug product manufactured, sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 219629 (including any supplements, or modification or amendments thereto or replacements thereof) (“GLAND’s ANDA”); (ii) the term “Licensed ARI Patent” shall mean United States Patent No. 11,998,565 (“the ’565 patent”) and 12,150,957 (“the ’957 Patent”); and (iii) the term “Affiliate” shall mean any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is

under common control with GLAND; for purposes of this definition, “control” means:

(a) ownership, directly or through one or more intermediaries, of: (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership; or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity.

3. Unless otherwise specifically authorized by ARI pursuant to the Settlement Agreement or by 35 U.S.C. § 271(e)(1), GLAND, including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed ARI Patent, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing of the GLAND Product in the United States.

4. Compliance with this Consent Judgment may be enforced by ARI, its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

5. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

6. All claims, counterclaims, affirmative defenses and demands in this Actions are hereby dismissed without prejudice and without costs, disbursements or attorneys’ fees to any party.

7. Nothing herein shall preclude the U.S. Food & Drug Administration from granting final approval to GLAND’s ANDA or shall preclude GLAND from filing, modifying,

---

amending, recertifying or maintaining with the FDA any Paragraph IV Certification for the GLAND Product pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV).

---

Brian R. Martinotti  
United States District Judge

We hereby consent to the form and entry of this Order:

s/ Charles H. Chevalier

Charles H. Chevalier  
GIBBONS P.C.  
One Gateway Center  
Newark, New Jersey 07102-5310  
(973) 596-4611  
[cchevail@gibbonslaw.com](mailto:cchevail@gibbonslaw.com)

Christine A. Gaddis  
GIBBONS P.C.  
141 West Front Street, Suite 240  
Red Bank, New Jersey 07701  
(732) 704-5801  
[cgaddis@gibbonslaw.com](mailto:cgaddis@gibbonslaw.com)

OF COUNSEL:

Dennies Varughese, Pharm. D.  
Uma Everet  
Adam LaRock  
Alex Alfano  
Ryan Conkin  
Sterne, Kessler, Goldstein & Fox  
P.L.L.C.  
1101 K Street, NW, 10th Floor  
Washington, DC 20005  
(202) 371-2600  
[dvarughese@sternekessler.com](mailto:dvarughese@sternekessler.com)  
[ueverett@sternekessler.com](mailto:ueverett@sternekessler.com)  
[alarock@sternekessler.com](mailto:alarock@sternekessler.com)  
[aalfano@sternekessler.com](mailto:aalfano@sternekessler.com)  
[rconkin@sternekessler.com](mailto:rconkin@sternekessler.com)

s/ R. Touhey Myer

R Touhey Myer (NJ Bar ID 028912009)  
800 N. West Street  
Wilmington, DE 19801  
(302) 527-9378  
[tmeyer@kratzandbarry.com](mailto:tmeyer@kratzandbarry.com)

Of Counsel:

Timothy H. Kratz  
George J. Barry III  
John Thallemer  
KRATZ & BARRY, LLP  
1050 Crown Pointe Parkway, Suite 500  
Atlanta, GA 30338  
(404) 431-6600  
[tkratz@kratzandbarry.com](mailto:tkratz@kratzandbarry.com)  
[gbarry@kratzandbarry.com](mailto:gbarry@kratzandbarry.com)

Michael P. Hogan  
KRATZ & BARRY LLP  
325 Chestnut Street, Suite 883, #259  
Philadelphia, PA 19106  
(917) 216-8585  
[mhogan@kratzandbarry.com](mailto:mhogan@kratzandbarry.com)

*Attorneys for Defendant Gland Pharma Limited*

*Attorneys for Plaintiff American  
Regent, Inc.*

|